The experiences of patients with pulmonary. arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons

被引:11
|
作者
Hall, Heather [1 ]
Cote, Joanne [2 ]
McBean, Althea [2 ]
Purden, Margaret [1 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Sch Nursing, Ctr Nursing Res, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Jewish Gen Hosp, Div Cardiol, Montreal, PQ H3T 1E2, Canada
来源
HEART & LUNG | 2012年 / 41卷 / 01期
关键词
Epoprostenol; Pulmonary arterial hypertension; Qualitative; Resilience; Support persons; Technology; QUALITY-OF-LIFE; RESILIENCE; THERAPY; HOME; PROSTACYCLIN;
D O I
10.1016/j.hrtlng.2011.05.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: Little is known about the day-to-day experiences of patients and their support persons during the course of epoprostenol treatment for pulmonary arterial hypertension (PAH). The study objective was to describe the experiences of patients and their support persons adjusting to PAH and continuous intravenous epoprostenol. METHODS: A qualitative descriptive design with semistructured interviews was conducted jointly with the patient and his/her support person. Seven patients and their support persons (spouse, child, friend) were included. RESULTS: Patients demonstrated personal growth and resilience as they adapted to PAH. Four patient themes emerged: initial shock, figuring it out, giving life, and ongoing struggles. Themes specific to the support person included "their life is in my hands," pressure to perform, and continuation of my role. CONCLUSION: Nurses may assist these patients and support persons by teaching technical skills, problem-solving and troubleshooting strategies, mobilizing social support, and providing opportunities to reflect on lifestyle changes and long-term adjustment to PAH. Cite this article: Hall, H., Cote, J., McBean, A., & Purden, M. (2012, JANUARY/FEBRUARY). The experiences of patients with pulmonary arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons. Heart & Lung, 41(1), 35-43. doi:10.1016/j.hrtlng.2011.05.007.
引用
收藏
页码:35 / 43
页数:9
相关论文
共 50 条
  • [21] Effects of continuous intravenous epoprostenol therapy on advanced primary pulmonary hypertension in Taiwanese patients
    Hsu, HH
    Chen, JS
    Kuo, SH
    Chiang, FT
    Ko, WJ
    Kuo, SW
    Huang, SC
    Lee, YC
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2005, 104 (01) : 60 - 63
  • [22] Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment
    Petkov, V
    Ziesche, R
    Mosgoeller, W
    Schenk, P
    Vonbank, K
    Stiebellehner, L
    Raderer, M
    Brunner, C
    Kneussl, M
    Block, LH
    THORAX, 2001, 56 (09) : 734 - 736
  • [23] Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)
    Tamura, Yuichi
    Ono, Tomohiko
    Fukuda, Keiichi
    Satoh, Toru
    Sasayama, Shigetake
    ADVANCES IN THERAPY, 2013, 30 (05) : 459 - 471
  • [24] Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension
    Ewert, Ralf
    Richter, Manuel J.
    Steringer-Mascherbauer, Regina
    Gruenig, Ekkehard
    Lange, Tobias J.
    Opitz, Christian F.
    Warnke, Christian
    Ghofrani, Hossein-Ardeschir
    CLINICAL RESEARCH IN CARDIOLOGY, 2017, 106 (10) : 776 - 783
  • [25] How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?
    Barst, R.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 : 23 - 32
  • [26] Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease
    Bakst, AE
    Gaine, SP
    Rubin, LJ
    CHEST, 1999, 116 (04) : 1127 - +
  • [27] Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension
    Tokunaga, Naoto
    Ogawa, Aiko
    Ito, Hiroshi
    Matsubara, Hiromi
    JOURNAL OF CARDIOLOGY, 2016, 68 (5-6) : 542 - 547
  • [28] Efficacy of acute inhalation of nitric oxide in patients with primary pulmonary hypertension using chronic use of continuous epoprostenol infusion
    Saji, K
    Sakuma, M
    Suzuki, J
    Takahashi, T
    Demachi, J
    Nawata, J
    Kitamukai, O
    Onoue, N
    Sugimura, K
    Tada, T
    Fukui, S
    Kagaya, Y
    Watanabe, J
    Shirato, K
    CIRCULATION JOURNAL, 2005, 69 (03) : 335 - 338
  • [29] Epoprostenol discontinuation in patients with pulmonary arterial hypertension: a complex medical and social problem
    Chebib, Nader
    Cottin, Vincent
    Taharo-Ag-Ralissoum, Martine
    Chuzeville, Michel
    Mornex, Jean-Francois
    PULMONARY CIRCULATION, 2018, 8 (01)
  • [30] Epoprostenol (Veletri®, Caripul®): A Review of Its Use in Patients with Pulmonary Arterial Hypertension
    Sarah L. Greig
    Lesley J. Scott
    Greg L. Plosker
    American Journal of Cardiovascular Drugs, 2014, 14 : 463 - 470